CL2020002805A1 - Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526) - Google Patents

Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)

Info

Publication number
CL2020002805A1
CL2020002805A1 CL2020002805A CL2020002805A CL2020002805A1 CL 2020002805 A1 CL2020002805 A1 CL 2020002805A1 CL 2020002805 A CL2020002805 A CL 2020002805A CL 2020002805 A CL2020002805 A CL 2020002805A CL 2020002805 A1 CL2020002805 A1 CL 2020002805A1
Authority
CL
Chile
Prior art keywords
modulator
identify
biological system
divisional
disease process
Prior art date
Application number
CL2020002805A
Other languages
English (en)
Inventor
Niven Rajin Narain
Rangaprasad Sarangarajan
Vivek K Vishnudas
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of CL2020002805A1 publication Critical patent/CL2020002805A1/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Probability & Statistics with Applications (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Abstract

Un método para proporcionar un modelo para un sistema biológico para su uso en un método de plataforma, que comprende: establecer un modelo para un sistema biológico, usando células asociadas con el sistema biológico, para representar un aspecto característico del sistema biológico, donde el modelo para el sistema biológico es útil para generar conjuntos de datos usados en el método de plataforma; proporcionando así un modelo para un sistema biológico para uso en un método de plataforma.
CL2020002805A 2011-03-02 2020-10-28 Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526) CL2020002805A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448587P 2011-03-02 2011-03-02
US201261593848P 2012-02-01 2012-02-01

Publications (1)

Publication Number Publication Date
CL2020002805A1 true CL2020002805A1 (es) 2021-04-30

Family

ID=46758320

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013002526A CL2013002526A1 (es) 2011-03-02 2013-09-02 Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad.
CL2020002805A CL2020002805A1 (es) 2011-03-02 2020-10-28 Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013002526A CL2013002526A1 (es) 2011-03-02 2013-09-02 Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad.

Country Status (20)

Country Link
US (3) US9886545B2 (es)
EP (1) EP2680925B1 (es)
JP (2) JP6105491B2 (es)
KR (1) KR102071081B1 (es)
CN (2) CN107273712B (es)
AU (2) AU2012223136B2 (es)
BR (1) BR112013022208A2 (es)
CA (1) CA2828972C (es)
CL (2) CL2013002526A1 (es)
CO (1) CO6801640A2 (es)
EA (1) EA201391245A1 (es)
ES (1) ES2777894T3 (es)
IL (2) IL228096B (es)
MX (1) MX358408B (es)
MY (2) MY181093A (es)
PE (2) PE20180776A1 (es)
PH (3) PH12013501802B1 (es)
SG (2) SG10201601224WA (es)
WO (1) WO2012119129A1 (es)
ZA (1) ZA201306453B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120077206A1 (en) 2003-07-12 2012-03-29 Accelr8 Technology Corporation Rapid Microbial Detection and Antimicrobial Susceptibility Testing
CA2956645A1 (en) 2003-07-12 2005-03-31 David A. Goldberg Sensitive and rapid biodetection
US9434937B2 (en) 2011-03-07 2016-09-06 Accelerate Diagnostics, Inc. Rapid cell purification systems
US10254204B2 (en) 2011-03-07 2019-04-09 Accelerate Diagnostics, Inc. Membrane-assisted purification
WO2013134315A1 (en) * 2012-03-05 2013-09-12 Berg Pharma Llc Compositions and methods for diagnosis and treatment of pervasive developmental disorder
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
AU2012376214B2 (en) * 2012-04-02 2019-02-14 Berg Llc Interrogatory cell-based assays and uses thereof
SG11201407569PA (en) 2012-05-22 2014-12-30 Berg Llc Interrogatory cell-based assays for identifying drug-induced toxicity markers
WO2014071316A1 (en) * 2012-11-02 2014-05-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. In silico identification of cancer molecular signaling pathways and drug candidates
WO2014072950A1 (en) * 2012-11-09 2014-05-15 Cellworks Research India Private Limited System and method for development of therapeutic solutions
US9677109B2 (en) 2013-03-15 2017-06-13 Accelerate Diagnostics, Inc. Rapid determination of microbial growth and antimicrobial susceptibility
WO2014193982A1 (en) * 2013-05-28 2014-12-04 Five3 Genomics, Llc Paradigm drug response networks
HK1217538A1 (zh) * 2013-07-01 2017-01-13 伊克斯塞拉公司 治疗的系统生物学方法
WO2015181284A1 (en) * 2014-05-28 2015-12-03 Vito Nv A method for the relative quantification of chemical compounds contained in a mixture of different biological samples
CN114203296B (zh) * 2014-09-11 2025-10-17 布普格生物制药公司 基于患者数据的用于健康护理诊断和治疗的贝叶斯因果关系网络模型
SG11201702490PA (en) 2014-10-10 2017-04-27 Akira Matsumori Method for detecting cardiac failure patient, method for discrimination of cardiac disease, test reagent for cardiac failure, test kit for cardiac failure, device for detecting cardiac failure, and program for detecting cardiac failure
EP4242329A3 (en) 2014-12-08 2023-10-25 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
US10253355B2 (en) 2015-03-30 2019-04-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
WO2016161022A2 (en) 2015-03-30 2016-10-06 Accerlate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
CN106250717B (zh) * 2015-06-04 2019-03-12 徐勇 急性髓性白血病的miRNA与转录因子的系统及其构建方法和应用
KR101881398B1 (ko) * 2016-04-07 2018-07-24 한국과학기술원 생물학적 시스템 정보 처리 장치 및 방법
US20200185063A1 (en) 2016-06-05 2020-06-11 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers
US10282588B2 (en) * 2016-06-09 2019-05-07 Siemens Healthcare Gmbh Image-based tumor phenotyping with machine learning from synthetic data
US11001891B2 (en) 2016-11-14 2021-05-11 Berg Llc Methods for treating Parkinson's disease
WO2018094204A1 (en) * 2016-11-17 2018-05-24 Arivale, Inc. Determining relationships between risks for biological conditions and dynamic analytes
CA3057420C (en) * 2017-05-12 2023-08-01 Laboratory Corporation Of America Holdings Systems and methods for biomarker identificaton
WO2019068623A1 (en) 2017-10-02 2019-04-11 Koninklijke Philips N.V. DETERMINING THE FUNCTIONAL STATE OF TYPES OF IMMUNE CELLS AND AN IMMUNE RESPONSE
CN109086570B (zh) * 2018-06-29 2020-09-04 迈凯基因科技有限公司 一种多数据库依次交互方法及装置
CN112639986B (zh) * 2018-06-29 2025-03-07 杰克逊实验室 用于标识选择性剪接事件的方法和装置
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
JP7185243B2 (ja) * 2019-07-09 2022-12-07 株式会社島津製作所 ｉＰＳ細胞の分化効率予測モデルの構築方法及びｉＰＳ細胞の分化効率予測方法
WO2021050760A1 (en) * 2019-09-11 2021-03-18 Recursion Pharmaceuticals, Inc. Systems and methods for pairwise inference of drug-gene interaction networks
EP4207205A4 (en) * 2020-08-31 2025-02-26 Takeda Pharmaceutical Company Limited Inference device, inference method, inference program, model generating method, inference service providing system, inference service providing method, and inference service providing program
CN112151109B (zh) * 2020-09-09 2023-08-25 中国科学院大连化学物理研究所 用于评价生物分子交联质谱鉴定随机性的半监督学习方法
CN112466403B (zh) * 2020-12-31 2022-06-14 广州基迪奥生物科技有限公司 一种细胞通讯分析方法及系统
KR102556312B1 (ko) 2021-04-12 2023-07-19 서울대학교병원 세뇨관 배양부 및 간질 배양부를 포함하는 신장 모사 장기 칩
US20220399092A1 (en) * 2021-06-10 2022-12-15 Rajant Health Inc. Ai-enabled health platform
CN114038504A (zh) * 2021-11-30 2022-02-11 周建伟 一种识别驱动肿瘤转移关键异质性分子的预测系统
WO2023102204A1 (en) * 2021-12-03 2023-06-08 The Trustees Of Indiana University Biomarker for type 1 diabetes
CN115346687B (zh) * 2022-08-08 2025-07-04 之江实验室 一种采用非线性动态分析辅助神经网络用于评估药物引起的心脏毒性的方法
CN115775594A (zh) * 2022-12-12 2023-03-10 南京医基云医疗数据研究院有限公司 生物组学调控关系分析方法及装置、电子设备、介质
CN116046877B (zh) * 2023-04-03 2024-03-15 深圳先进技术研究院 疾病模型代谢分析方法、包埋模具及喷涂装置
WO2025259359A1 (en) * 2024-06-12 2025-12-18 CytoVale Inc. Systems and methods for sepsis determination

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US5918200A (en) 1992-08-31 1999-06-29 Yamatake-Honeywell Co., Ltd. State estimating apparatus
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
ATE220114T1 (de) 1993-03-19 2002-07-15 Sequenom Inc Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
EP1077724A2 (en) * 1998-04-17 2001-02-28 The University Of Vermont Methods and products related to metabolic interactions in disease
US6763307B2 (en) 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
CA2441060A1 (en) * 2001-03-13 2002-09-19 Ashni Naturaceuticals, Inc. Method for association of genomic and proteomic pathways associated with physiological or pathophysiological processes
US8000949B2 (en) 2001-06-18 2011-08-16 Genego, Inc. Methods for identification of novel protein drug targets and biomarkers utilizing functional networks
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7415359B2 (en) 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
DK1540505T3 (da) 2002-08-29 2008-10-13 Gene Network Sciences Inc Systemer og fremgangsmåder til dannelse af biologiske net
CN1714371A (zh) * 2002-11-19 2005-12-28 Gni美国公司 根据时间序列基因表达数据的基因网络的非线性模拟
JP4288345B2 (ja) 2003-06-19 2009-07-01 独立行政法人産業技術総合研究所 新規てんかんモデル動物
EP1512970A1 (en) * 2003-09-05 2005-03-09 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for determining the impact of a multicomponent mixture on the biological profile of a disease
JPWO2005035780A1 (ja) 2003-10-14 2006-12-21 株式会社セルフリーサイエンス 指標物質の新規スクリーニング方法
WO2005107412A2 (en) 2004-04-30 2005-11-17 Rosetta Inpharmatics Llc Systems and methods for reconstruction gene networks in segregating populations
EP1607898A3 (en) 2004-05-18 2006-03-29 Neal E. Solomon A bioinformatics system for functional proteomics modelling
US20100316629A1 (en) 2004-09-01 2010-12-16 Shaughnessy Jr John D Use of gene expression profiling to predict survival in cancer patient
JP2008528975A (ja) * 2005-01-24 2008-07-31 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 細胞シグナル伝達系のモデリングのためのベイジアンネットワークの使用
WO2006103615A1 (en) 2005-03-31 2006-10-05 Koninklijke Philips Electronics N.V. System and method for collecting evidence pertaining to relationships between biomolecules and diseases
US20090132171A1 (en) * 2005-05-31 2009-05-21 Jcl Bioassay Corporation Screening Method for Specific Protein in Proteome Comprehensive Analysis
CA2622852A1 (en) 2005-09-30 2007-04-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1978085A4 (en) * 2006-01-27 2010-12-01 Takeda Pharmaceutical Gene expression analysis TOOL
US8571803B2 (en) * 2006-11-15 2013-10-29 Gene Network Sciences, Inc. Systems and methods for modeling and analyzing networks
CN101105841B (zh) * 2007-02-12 2011-06-15 浙江大学 由大规模基因芯片表达谱数据构建基因调控亚网络的方法
US8140270B2 (en) * 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
AU2008284225B2 (en) 2007-05-16 2013-06-06 Edsa Micro Corporation Real-time predictive systems for intelligent energy monitoring and management of electrical power networks
JP2009050171A (ja) 2007-08-23 2009-03-12 Toyobo Co Ltd 表面プラズモン共鳴による基板上におけるリン酸化の検出方法
US7895146B2 (en) * 2007-12-03 2011-02-22 Microsoft Corporation Time modulated generative probabilistic models for automated causal discovery that monitors times of packets
WO2009114185A2 (en) * 2008-03-12 2009-09-17 The Rockefeller University Methods and compositions for translational profiling and molecular phenotyping
KR20110044905A (ko) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
BRPI1010576A2 (pt) 2009-05-11 2016-03-15 Berg Biosystems Llc métodos para tratamento de distúrbios oncológicos usando transferidores epimetabólicos, moléculas intracelulares multidimensionais ou influenciadores ambientais.
US20130023574A1 (en) 2010-03-31 2013-01-24 National University Corporation Kumamoto University Method for generating data set for integrated proteomics, integrated proteomics method using data set for integrated proteomics that is generated by the generation method, and method for identifying causative substance using same
AU2012376214B2 (en) * 2012-04-02 2019-02-14 Berg Llc Interrogatory cell-based assays and uses thereof
HK1217538A1 (zh) * 2013-07-01 2017-01-13 伊克斯塞拉公司 治疗的系统生物学方法

Also Published As

Publication number Publication date
IL257824A (en) 2018-04-30
SG193006A1 (en) 2013-10-30
JP2014512520A (ja) 2014-05-22
CN107273712A (zh) 2017-10-20
BR112013022208A2 (pt) 2022-03-08
MX2013010068A (es) 2013-11-01
US20180260515A1 (en) 2018-09-13
CL2013002526A1 (es) 2014-04-25
CN103501859A (zh) 2014-01-08
PE20140627A1 (es) 2014-05-30
KR20140013006A (ko) 2014-02-04
MX358408B (es) 2018-08-20
EP2680925B1 (en) 2019-11-20
CN103501859B (zh) 2017-08-25
IL228096B (en) 2018-03-29
NZ712105A (en) 2017-05-26
ZA201306453B (en) 2021-05-26
JP2017148046A (ja) 2017-08-31
US20120258874A1 (en) 2012-10-11
WO2012119129A1 (en) 2012-09-07
ES2777894T3 (es) 2020-08-06
KR102071081B1 (ko) 2020-01-29
MY164530A (en) 2017-12-29
EA201391245A1 (ru) 2014-05-30
AU2012223136A1 (en) 2013-09-19
MY181093A (en) 2020-12-17
PH12013501802B1 (en) 2018-06-27
CO6801640A2 (es) 2013-11-29
US11456054B2 (en) 2022-09-27
CN107273712B (zh) 2021-12-03
EP2680925A4 (en) 2014-12-31
AU2017202977B2 (en) 2019-09-19
PE20180776A1 (es) 2018-05-07
PH12017502073A1 (en) 2019-01-14
AU2017202977A1 (en) 2017-05-25
EP2680925A1 (en) 2014-01-08
AU2012223136B2 (en) 2017-05-25
NZ614891A (en) 2016-01-29
PH12017502072A1 (en) 2019-01-14
CA2828972A1 (en) 2012-09-07
IL228096A0 (en) 2013-09-30
US20240062844A1 (en) 2024-02-22
JP6105491B2 (ja) 2017-03-29
CA2828972C (en) 2021-09-07
PH12013501802A1 (en) 2013-11-18
SG10201601224WA (en) 2016-03-30
US9886545B2 (en) 2018-02-06

Similar Documents

Publication Publication Date Title
CL2020002805A1 (es) Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)
MX357392B (es) Ensayos basados en interrogatorios celulares y uso de los mismos.
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
BR112013011083A2 (pt) processo e sistema para treinamento pessoal automatizado
MX2016008251A (es) Medios para cultivo celular.
BR112015017174A2 (pt) preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
CL2015003599A1 (es) Solucion que contiene theralosa y dextrano para transplantar celulas de mamiferos
UY32509A (es) Sistema y método para identificar árboles mediante el uso de modelos lidar de árboles
AR088322A1 (es) Anticuerpos anti-htra1 y metodos de uso
MX376437B (es) Uso de hígado descelularizado por perfusión para recelularización de células de islote.
BR112015021189A2 (pt) métodos de banco de células de alta densidade
AR081151A1 (es) Metodo para producir bacterias pertenecientes al genero bifidobacterium
AR090319A1 (es) Biorrefineria integrada
AR079704A1 (es) Anticuerpos anti-bv8 y sus usos
CL2014003055A1 (es) Procedimiento para preparar una composicion farmaceutica que comprende i) proporcionar una primera combinacion que comprende un compuesto inhibidor del proteasoma peptidico, una o mas ciclodextrinas y agua, y ii) poner en contacto la primera combinacion con un acido para formar una segunda combinacion; composicion farmaceutica.
IN2012DE00401A (es)
CL2016000746A1 (es) Un método para producir un l-aminoácido usando una bacteria de la familia de las enterobacteriaceae teniendo atenuada la expresión de un gen que codifica un transportador de fosfato
CR20140444A (es) Un sistema y un método para la producción integrada de etanol de primera y segunda generación, y uso de puntos de integración para dicha producción
BR112014006911A2 (pt) aditivos de perda de fluido e métodos de produção e uso dos mesmos
AR085824A1 (es) Anticuerpo anti-receptor il-3 humano
BR112016006383A8 (pt) métodos para extração de uma proteína solúvel, produção de uma composição e produção de um suporte sólido ou semissólido
EA201791659A1 (ru) Компьютеризированный способ создания модели процесса ферментации
BR112014005383C8 (pt) complexo bis-iminopiridina de lantanídeos, sistema catalítico compreendendo o dito complexo bis-iminopiridina e processo para a (co)polimerização de dienos conjugados
AR086030A1 (es) Metodos y dispositivos para amplificar acidos nucleicos